Biocon Limited BIOCON

Latest filings

• Approval68 25 Sept, 08:35 · NSE
  'Company Statement'.
• General25 21 Sept, 08:26 · NSE
  A press release dated September 21, 2026, titled "Biocon s Pertuzumab Becomes First Biosimilar to Secure EMA CHMP Approval Recommendation Under New Tailored Clinical Approach".
• Dividend51 9 Sept, 13:58 · NSE
  Communication regarding remittance of final dividend for the FY 2025-26
• Routine15 8 Sept, 16:03 · BSE
  Intimation of Schedule of Meetings with Analyst(s)/Institutional Investor(s)
• Routine15 8 Sept, 15:57 · NSE
  Schedule of meet
• Order win70 8 Sept, 08:31 · NSE
  A press release dated September 08, 2026, titled "Biocon Secures 10-Year Supply Contract for Pertuzumab in Brazil".
• Routine15 31 Aug, 18:02 · BSE
  Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
• Dividend51 28 Aug, 20:58 · BSE
  Biocon Ltd - 532523 - Communication Regarding Remittance Of Final Dividend For The FY 2025-26
• Insider / SAST45 26 Aug, 14:51 · BSE
  Biocon Ltd - 532523 - Revised Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
• General25 25 Aug, 08:28 · NSE
  'Company Statement'.

Shown 15 minutes after publication. Real time with Pro.

Upcoming corporate actions

No announced actions in the next 60 days.